Year: 2016
Type: article
Study design: Observational Study
Abstract: Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates.Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns.Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC.Methods: Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3,024 consecutive patients from 29 international academic centers from 2005 to 2013.Patients with clinical T2-T4aN0M0 urothelial cancer of the bladder were included.
Source: Bladder Cancer
DOI: 10.3233/blc-160072
Authors: Tracy L. Rose, the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators, Allison M. Deal, Sylvain Ladoire, Gilles Créhange, Matthew D. Galsky, Jonathan E. Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C. Harshman, Simon Chowdhury, Guenter Niegisch, Michalis Liontos, Evan Y. Yu, Sumanta K. Pal, Ronald C. Chen, Andrew Z. Wang, Matthew E. Nielsen, Angela B. Smith, Matthew I. Milowsky
Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Université de Bourgogne, Centre Georges François Leclerc, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Queen Mary University of London, The Royal Free Hospital, Barts Cancer Institute, Fox Chase Cancer Center, Temple University Health System, St Thomas' Hospital, Guy's Hospital, Heinrich Heine University Düsseldorf, National and Kapodistrian University of Athens, Fred Hutch Cancer Center, City Of Hope National Medical Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, Novartis, Celgene, Exelixis, Les Laboratories Pierre Fabre, Accuray, Mirati Therapeutics, Astellas Pharma, National Institutes of Health, Genentech, Takeda Oncology, National Cancer Institute, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: G1192852400, G137891388, G156276794, Carolina Center of Cancer Nanotechnology Excellence, G2904540500, G4720334866, G5817892181, Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapy, G9000013544, G9000037730, G9000128505, Cancer Center Support Grant, UNC Oncology Clinical Translational Research Training Program
OpenAlex ID: W2532767791